Optimal risk factor modification and medical management of the patient with peripheral arterial disease

被引:36
作者
Chi, Yung-Wei [1 ]
Jaff, Michael R. [2 ]
机构
[1] Ochsner Clin Fdn, Ochsner Heatr & Vasc Inst, Dept Cardiol, Sect Vasc Med, New Orleans, LA USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Vasc Med, Boston, MA USA
关键词
medical management; peripheral arterial occlusive disease; risk factor modification;
D O I
10.1002/ccd.21401
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Peripheral arterial occlusive disease (PAD) is a highly prevalent atherosclerotic syndrome associated with significant morbidity and mortality. It is defined by atherosclerotic obstruction of the abdominal aorta and arteries to the legs that reduces arterial flow during exercise and/or at rest, and is a common manifestation of systemic atherosclerosis. PAD represents a marker for premature cardiovascular events, and in patients with PAD, even in the absence of a history of myocardial infarction (MI) or ischemic stroke, they have approximately the same relative risk of death from cardiovascular causes as do patients with a history of coronary or cerebrovascular disease. In addition, their death rate from all causes is approximately equal in men and women and is elevated even in asymptomatic patients. The major risk factors for PAD are the well defined atherosclerotic risks such as diabetes mellitus, cigarette smoking, advanced age, hyperlipidemia, and hypertension. Due to the presence of these risk factors, the systemic nature of atherosclerosis, and the high risk of ischemic events, patients with PAD should be candidates for aggressive secondary prevention strategies including aggressive risk factor modification, antiplatelet therapy, lipid lowering therapy and antihypertensive treatment. This article reviews the current medical treatment and risk factor modification of patients with PAD. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:475 / 489
页数:15
相关论文
共 131 条
  • [21] Decreased NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease
    Brass, EP
    Hiatt, WR
    Gardner, AW
    Hoppel, CL
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2001, 280 (02): : H603 - H609
  • [22] Acquired skeletal muscle metabolic myopathy in atherosclerotic peripheral arterial disease
    Brass, EP
    Hiatt, WR
    [J]. VASCULAR MEDICINE, 2000, 5 (01) : 55 - 59
  • [23] SUPERIORITY OF L-PROPIONYLCARNITINE VS L-CARNITINE IN IMPROVING WALKING CAPACITY IN PATIENTS WITH PERIPHERAL VASCULAR-DISEASE - AN ACUTE, INTRAVENOUS, DOUBLE-BLIND, CROSS-OVER STUDY
    BREVETTI, G
    PERNA, S
    SABBA, C
    ROSSINI, A
    DIUCCIO, VS
    BERARDI, E
    GODI, L
    [J]. EUROPEAN HEART JOURNAL, 1992, 13 (02) : 251 - 255
  • [24] Impact of cholesterol reduction on peripheral arterial disease in the Program on the Surgical Control of the Hyperlipidemias (POSCH)
    Buchwald, H
    Bourdages, HR
    Campos, CT
    Nguyen, P
    Williams, SE
    Boen, JR
    [J]. SURGERY, 1996, 120 (04) : 672 - 679
  • [25] Platelet activation is increased in peripheral arterial disease
    Cassar, K
    Bachoo, P
    Ford, I
    Greaves, M
    Brittenden, J
    [J]. JOURNAL OF VASCULAR SURGERY, 2003, 38 (01) : 99 - 103
  • [26] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    Chobanian, AV
    Bakris, GL
    Black, HR
    Cushman, WC
    Green, LA
    Izzo, JL
    Jones, DW
    Materson, BJ
    Oparil, S
    Wright, JT
    Roccella, EJ
    [J]. HYPERTENSION, 2003, 42 (06) : 1206 - 1252
  • [27] Cholesterol in peripheral vascular disease - a suitable case for treatment?
    Clark, AL
    Byrne, JC
    Nasser, A
    McGroarty, E
    Kennedy, JA
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 1999, 92 (04) : 219 - 222
  • [28] Clark N, 2003, DIABETES CARE, V26, P3333
  • [29] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [30] COFFMAN JD, 1979, NEW ENGL J MED, V300, P713